SEARCH

SEARCH BY CITATION

References

  • 1
    Thomas S.M., Brugge J.S. (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol;13:513609.
  • 2
    Nam J.S., Ino Y., Sakamoto M., Hirohashi S. (2002) Src family kinase inhibitor pp2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res;8:24302436.
  • 3
    Aligayer H., Boyd D.D., Heiss M.M., Abdalla E.K., Curley S.A., Gallick G.E. (2002) Activation of Src kinase in primary colorectal carcinoma:an indicator of poor clinical prognosis. Cancer;94:344351.
  • 4
    Irby R.B., Yeatman T.J. (2002) Increased Src activity disrupts cadherin/catenin-mediated homotypic adhesion in human colon cancer and transformed rodent cells. Cancer Res;62:26692674.
  • 5
    Belsches-Jablonski A.P., Biscardi J.S., Peavy D.R., Tice D.A., Romney D.A., Parsons S.J. (2001) Src family kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene;20:14651475.
  • 6
    MacMillan-Crow L.A., Greendorfer J.S., Vickers S.M., Thompson J.A. (2000) Tyrosine nitration of c-Src tyrosine kinase in human pancreatic ductal adenocarcinoma. Arch Biochem Biophys;377:350356.
  • 7
    Levitzk A., Gazit A. (1995) Tyrosine kinase inhibition: an approach to drug development. Science;267:17821788.
  • 8
    Maly D.J., Choong I.C., Ellman J.A. (2000) Combinatorial target-guided ligand assembly identification of potent subtype-selective c-Src inhibitors. Proc Natl Acad Sci;97:24192424.
  • 9
    Dow R.L., Bechle B.M., Chou T.T., Goddard C., Larson E.R. (1995) Selective inhibition of the tyrosine kinase pp60c-src by analogs of 5,10 dihydropyrimido (4,5-b)quinolin-4(1H)-one. Bioorg Med Chem Lett;5:10071010.
  • 10
    Carraro F., Naldini A., Pucci A., Locatelli G.A., Maga G., Schenone S., Bruno O. et al. (2006) Pyrazolo[3,4-d]pyrimidines as potent antiproliferative and proapoptotic agents toward A431 and 8701-BC cells in culture via inhibition of c-Src phosphorylation. J Med Chem;49:15491561.
  • 11
    Altmann E., Widler L., Missbach M. (2002) N(7)-substituted-5-aryl-pyrrolo[2,3-d] pyrimidines represent a versatile class of potent inhibitors of the tyrosine kinase c-Src. Mini Rev Med Chem;2:201208.
  • 12
    Thompson A.M., Rewcastle G.W., Biushelle S.I., Hartl B.G., Kraker A.J., Lu G.H., Batley B.L., Panek R.L., Showalter H.D.H., Denny W.A. (2000) Synthesis and structure−activity relationships of 7-substituted 3-(2,6-Dichlorophenyl)-1,6- naphthyridin-2(1H)-ones as selective inhibitors of pp60c-src. J Med Chem;43:31343147.
  • 13
    Plé P.A., Green T.P., Hennequin L.F., Curwen J., Fennell M., Allen J., Lambert-van der Brempt C., Costello G. (2004) Discovery of a new class of anilinoquinazoline inhibitor with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem;47:871887.
  • 14
    Shah N.P., Tran C., Lee F.Y., Chen P., Norris D., Sawyers C.L. (2004) Overriding Imatinib resistance with a novel Abl kinase inhibitor. Science;305:399401.
  • 15
    Boschelli D.H., Wang Y.D., Biqi Wu F.Y., Zhang N., Dutia M., Powell D.W., Wissner A., Arndt K., Weber J.M., Boschelli F. (2001) Synthesis and Src kinase inhibitory activity of a series of 4-phenylamino-3-quinolinecarbonitriles. J Med Chem;44:822833.
  • 16
    Berger D., Dutia M., Powell D., Wissner A., De Morin F., Raifeld Y., Bosch J., Boschelli F. (2002) Substituted 4-anilino-7-phenyl-3-quinolinecarbonitriles as Src kinase inhibitors. Bioorg Med Chem Lett;12:29892992.
  • 17
    Boschell D.H., Wang Y.D., Johnson S., Wu B., Yu F., Barrios Sosa A.C., Golas J.M., Boschelli D.H., Boschelli F. (2004) 7-Alkoxy-4-phenylamino-3- quinolinecarbonitriles as dual inhibitors of Src and Abl kinases. J Med Chem;47:15991601.
  • 18
    Barrios Sosa A.C., Boschelli D.H., Wu B.Q., Wang Y., Golas J.M. (2005) Further studies on ethenyl and ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of a subnanomolar Src kinase inhibitor. Bioorg Med Chem Lett;15:17431747.
  • 19
    Wu B.Q., Barrios Sosa A.C., Boschelli D.H., Boschelli F., Honores E.E., Golas J.M., Powell D.W., Wang Y.D. (2006) 7-(Aryl/heteroaryl-2-ylethynyl)-4- phenylamino-3-quinolinecarbonitriles as new Src kinase inhibitors: addition of water solubilizing groups. Bioorg Med Chem Lett;16:39933997.
  • 20
    Boschelli D.H., Barrios Sosa A.C., Golas J.M., Boschelli F. (2007) Inhibition of Src kinase activity by 7-ethynyl-4-phenylamino-3-quinolinecarbonitriles: identification of SKS-927. Bioorg Med Chem Lett;17:13581361.
  • 21
    Thaimattam R., Daga P.R., Banerjee R., Iqbal J. (2005) 3D-QSAR studies on c-Src kinase inhibitors and docking analyses of a potent dual kinase inhibitor of c-Src and c-Abl kinases. Bioorg Med Chem;13:47044712.
  • 22
    Sun M., Zheng Y.G., Wei H.T., Chen J.Q., Cai J., Ji M. (2009) Enhanced replacement method-based quantitative structure-activity relationship modeling and support vector machine classification of 4-anilino-3-quinolinecarbonitriles as Src kinase inhibitors. QSAR Comb Sci;28:312324.
  • 23
    Wu W.J., Chen J.C., Qian L., Zheng K.C. (2007) Qsar and molecular design of benzo[b] acronycine derivatives as antitumor agents. J Theor Comput Chem;2:223231.
  • 24
    Veras Lea da S., Arakawa M., Funatsu K., Takahata Y. (2010) 2D and 3D QSAR studies of the receptor binding affinity of progestins. J Braz Chem Soc;5:872881.
  • 25
    Sekhar Y.N., Nayana M.R.S., Ravikumar M., Mahmood S.K. (2007) Comparative molecular field analysis of quinoline derivatives as selective and noncompetitive mGluR1 antagonists. Chem Biol Drug Des;70:511519.
  • 26
    Liao S.Y., Chen T.J., Miao T.F., Qian L., Zheng K.C. (2009) Binding orientations,QSAR,and molecular design of thiophene derivative inhibitors. Chem Bio Drug Des;74:289296.
  • 27
    Turabekova M.A., Rasulev B.F., Dzhakhangirov F.N., Leszczynska D., Leszczynski J. (2010) Aconitum and Delphinium alkaloids of curare-like activity. QSAR analysis and molecular docking of alkaloids into AchBP. Eur J Med Chem;45:38853894.
  • 28
    Becke A.D. (1993) A new mixing of Hartree-Fock and local density functional theories. J Chem Phys;98:13721377.
  • 29
    De K., Sengupta C., Roy K. (2004) QSAR modeling of globulin binding affinity of corticosteroids using AM1 calculations. Bioorg Med Chem;12:33233332.
  • 30
    Cho S.J., Tropsha A. (1995) Cross-validated R2-guided region selection for comparative molecular field analysis: a simple method to achieve consistent results. J Med Chem;38:10601066.
  • 31
    Roy D.R., Sarkar U., Chattaraj P.K., Mitra A., Padmanabhan J., Parthasarathi R., Subramanian V., Van Damme S., Bultinck P. (2006) Analyzing toxicity through electrophilicity. Mol Divers;10:119131.
  • 32
    Zhang S., Wei L., Bastow K., Zheng W., Brossi A., Lee K.H., Tropsha A. (2007) Antitumor Agents 252. Application of validated QSAR models to database mining: discovery of novel tylophorine derivatives as potential anticancer agents. J Comput Aided Mol Des;21:97112.
  • 33
    Cramer R.D. III, Pattersson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:59595967.
  • 34
    Tetko I.V., Tanchuk V.Y., Villa A.E. (2001) Prediction of n-octanol/water partition coefficients from PHYSPROP database using artificial neural networks and E-state indices. J Chem Inf Comput Sci;41:14071421.
  • 35
    Chen J.C., Shen Y., Liao S.Y., Chen L.M., Zheng K.C. (2006) DFT-based QSAR study and molecular design of AHMA derivatives as potent anticancer agents. Int J Quantum Chem;107:14681478.
  • 36
    Liao S.Y., Qian L., Lu H.L., Shen Y., Zheng K.C. (2008) A combined 2D- and 3D-QSAR study on analogues of ARC-111 with antitumor activity. QSAR Comb Sci;27:740749.
  • 37
    Hennequin L.F., Allen J., Breed J., Curwen J., Fennell M., Green T.P., Lambert-van der Brempt C., Morgentin R., Norman R.A., Olivier A., Otterbein L., Plé P.A., Warin N., Costello G. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2- (4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4- amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem;49:64656488.
  • 38
    Pople J.A., Gordon M.S. (1967) Molecular orbital theory of the electronic structure of organic compounds. I. Substituent effects and dipole moments. J Am Chem Soc;89:42534261.
  • 39
    Hennequin L.F., Stokes E.S., Thomas A.P., Johnstone C., Plé P.A., Ogilvie D.J., Dukes M., Wedge S.R., Kendrew J., Curwen J.O. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem;45:13001312.
  • 40
    Zheng K.C., Wang J.P., Peng W.L., Liu X.W., Yun F.C. (2001) Studies on 6,6-disubstitution effects of the dpq in [Ru(bpy)(2) (dpq)](2+) with DFT method. J Phys Chem A;105:1089910905.